Geron and Proctor & Gamble, SurroMed and Merck, Discovery Partners International, Becton Dickinson and Molecular Devices, Modular Genetics, Qiagen and AstraZeneca, and Life Science Insights | GenomeWeb

Geron to License hTERT Technology to Proctor & Gamble

Geron has granted a nonexclusive license to Proctor & Gamble for its human telomerase reverse transcriptase technology for research applications, it said on July 7. Financial terms of the agreement were not disclosed.

P & G will use hTERT to create immortalized cell lines from certain types of skin cells, and use the cells to study the regulation of cell function and develop biological assays for drug screening, Geron said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.